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Background: This study evaluates the geographic expression pattern of Raf-1 Kinase Inhibitor Protein (RKIP) in colorectal cancer
(CRC) in correlation with clinicopathological and molecular features, markers of epithelial-mesenchymal transition (EMT) and
survival outcome.
Methods:Whole-tissue sections of 220 well-characterised CRCs were immunostained for RKIP. NF-kB and E-Cadherin expression
was assessed using a matched multi-punch tissue microarray. Analysis of mismatch repair (MMR) protein expression, B-Raf and
KRAS mutations was performed. RKIP expression in normal mucosa, tumour centre, invasion front and tumour buds was each
assessed for clinical relevance.
Results: RKIP was diffusely expressed in normal mucosa and progressively lost towards tumour centre and front (Po0.0001).
Only 0.9% of tumour buds were RKIP-positive. In the tumour centre, RKIP deficiency predicted metastatic disease (P¼ 0.0307),
vascular invasion (P¼ 0.0506), tumour budding (P¼ 0.0112) and an invasive border configuration (P¼ 0.0084). Loss of RKIP
correlated with NF-kB activation (P¼ 0.0002) and loss of E-Cadherin (Po0.0001). Absence of RKIP was more common in
MMR-deficient cancers (P¼ 0.0191), while no impact of KRAS and B-Raf mutation was observed. RKIP in the tumour centre was
identified as a strong prognostic indicator (HR (95% CI): 2.13 (1.27–3.56); P¼ 0.0042) independently of TNM classification and
therapy (P¼ 0.0474).
Conclusion: The clinical relevance of RKIP expression as an independent prognostic factor is restricted to the tumour centre. Loss
of RKIP predicts features of EMT and correlates with frequent distant metastasis.
RKIP is a ubiquitously expressed phospholipid-binding protein
that functions as an endogenous inhibitor of the Ras/Raf/MEK/
ERK signalling cascade (Yeung et al, 1999). RKIP inhibits this
pathway at the level of Raf. It binds both Raf and MEK, inhibiting
their association and the phosphorylation of MEK, thereby turning
off the signalling pathway (Supplementary Figure 1A). Subse-
quently, it was shown that RKIP suppresses the activation of the
NF-kB/SNAIL circuit (Supplementary Figure 1B) (Wu and
Bonavida, 2009). This pathway has an important role for the
induction of epithelial-mesenchymal transition (EMT) of cancer
cells as one of the initial steps for the induction of metastasis
(Wu and Bonavida, 2009). The histopathological hallmark of EMT
is thought to be the presence of single tumour cells or small
clusters (o5) of dedifferentiated cells at the invasive front of CRC,
termed tumour budding (Jass et al, 1986).
A reduced expression of RKIP has been identified as a common
feature in malignant tumours with a further decrease in metastatic
disease (Fu et al, 2003; Hagan et al, 2005). Using animal models,
conclusive evidence has been provided that RKIP impairs
invasiveness and the ability to form metastases in cancer cells
(Fu et al, 2003). Loss of RKIP protein has been identified as a
significant prognostic factor in prostate cancer (Fu et al, 2006),
CRC (Al-Mulla et al, 2006; Minoo et al, 2007; Zlobec et al, 2008;
Doyle et al, 2013), GIST (Martinho et al, 2009), pancreas (Kim
et al, 2010), lung (Huerta-Yepez et al, 2011), and very recently in
oesophagus (Kim et al, 2012), stomach (Fujimori et al, 2012) and
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malignant glioma (Martinho et al, 2012). The fact that the protein
expression of RKIP shows a strong correlation with survival
outcome in a variety of malignancies of epithelial, mesenchymal
and glial origin highlights the potential value of this biomarker for
prospective clinical trials.
In colorectal cancer (CRC), several studies based on single-
punch tissue microarrays (TMA) demonstrated a significant
correlation between RKIP expression and overall survival in
CRC: Al-Mulla et al (2006) provided first evidence that RKIP
protein expression in primary CRC strongly correlates with the
overall survival independent of stage and may be used efficiently
for risk stratification. Consecutively, Minoo et al (2007) demon-
strated that the assessment of RKIP protein expression by
immunohistochemistry is highly reproducible (ICC¼ 0.75) and
confirmed the predictive value of RKIP expression for overall
survival and metastases in both MMR-proficient and deficient
tumours in a large cohort of over 1000 CRC patients. Further, it
was demonstrated by our group that RKIP status can be combined
with N-stage and vascular invasion to provide independent
predictive information on metastatic disease (Zlobec et al, 2008).
In TMA-based profiling of multi-marker phenotypes of CRC, we
identified RKIP as a predictor of high-grade tumour budding in
univariate, but not in multivariate analysis (Karamitopoulou et al,
2010) that is differentially expressed between tumour centre and
tumour front (Karamitopoulou et al, 2011).
Taken together, these studies suggest that RKIP may be able to
serve as a valuable biomarker to identify aggressive CRC that should
be considered for adjuvant therapy. However, recent studies provide
conclusive evidence that malignant tumours demonstrate extensive
genetic heterogeneity (Gerlinger et al, 2012). It is therefore
important to evaluate the intratumoural heterogeneity of immuno-
histochemical marker expression on large bore TMAs or whole-
tissue sections to confirm the prognostic and predictive value of
promising biomarkers in the context of molecular characteristics.
Consequently, the aim of this study was the geographic analysis of
RKIP expression in all histological areas of CRC and to determine
the correlation of RKIP expression pattern with clinicopathological
characteristics, molecular features and survival outcome.
MATERIALS AND METHODS
Patient cohort. Two hundred and twenty unselected, non-
consecutive CRC patients treated at the Aretaieion University
Hospital, University of Athens, Greece between the years 2004 and
2007 were included in this study (Figure 1). Clinical data including
patient gender, age at diagnosis, tumour diameter, tumour
location, post-operative therapy information and disease-specific
survival time were retrieved from patient records. The histomor-
phological data were reviewed by an experienced gastrointestinal
pathologist (EK) and includes histological subtype, tumour grade,
pT classification, lymphatic and venous invasion, nodal status,
tumour growth pattern and tumour budding. Tumour budding
was quantified in 10HPF along the invasive front of each case
(Karamitopoulou et al, 2013). The average survival time was 47
months (35–58 months). Patient characteristics are summarised in
Table 1; where indicated by a lower case number, information for
single patients on one of the clinicopathological features was not
available. Information on the number of patients receiving
chemotherapeutic treatment within each subset is indicated in
Tables 2 and 3 and Supplementary Table S3; further information
on therapy and performance status is provided in Supplementary
Tables S1 and S2. The use of patient data has been approved by the
local Ethics Committee of the University of Athens, Greece.
Analysis. Antibodies for RKIP (Merck Millipore, Billerica,
MA, USA; Cat no. 07–137; rabbit anti-human RKIP, polyclonal)
were used at a dilution of 1 : 1000. RKIP staining was performed
using a Bond Max Autostainer from Leica Microsystems (Wetzlar,
Germany) with antigen retrieval performed in citrate buffer at 100
1C for 20min. For every case, the percentage of RKIP-positive cells
per HPF was evaluated in a total of 35 randomly selected high-
power fields (HPFs) in the tumour centre, invasion front, tumour
buds (10HPF each) and normal mucosa (5 HPF) independent of
staining intensity (Figure 2A and B). Normal colonic mucosa and
nerve tissue served as an internal positive control; negative controls
were performed without primary antibody. Isotype controls were
n =220 colorectal cancers
Association of RKIP expression in each geographic area with prognostic features,
tumor morphology, survival time, markers of EMT and molecular characteristics
Molecular classification
Patient age, gender, tumor size, tumor
location, information on post-operative
therapy and disease-specific survival time.
Full pTNM classification including L,V,
grade, histological subtype, growth pattern
and tumor budding. 
-Mismatch repair protein expression
-B-Raf mutation (V600E)
-KRAS mutation (codon12/13)
Geographic analysis of RKIP expression in 10 HPF of tumor center,
tumor front, tumor buds and normal mucosa (n =187)
Exclusion: Cases without clearly defined histological zones (n =33)
Immunohistochemistry for RKIP on full tissue sections
immunohistochemistry for E-Cadherin and NF-κB on a matched TMA
Clinicopathological characterization
Figure 1. Study design: 220 CRC patients were entered into the study. Cases were reviewed for clinicopathological features and characterised for
B-Raf, KRAS mutations and MMR protein expression. Immunohistochemistry for RKIP was performed on full-tissue sections. Geographic analysis of
RKIP expression patterns was performed in 10HPF each of tumour centre, tumour front and tumour buds as well as normal mucosa (5 HPF).
Expression of E-Cadherin and NF-kB was assessed on a matched multi-punch TMA. The association of RKIP protein expression with prognostic
features, tumour morphology, survival time, markers of EMT and molecular characteristics was carried out for each histological zone.
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established using a matched multi-punch test TMA of CRC and
normal mucosa (Figure 2C). Based on receiver operating
characteristic (ROC)-curve analysis for survival, tumour regions
with410% of RKIP-positive cells were classified as positive. Cases
that did not allow a clear definition of the different histological
zones were excluded from the analysis (33 cases). This exclusion
criterion occurred randomly. The average expression in tumour
centre, front and tumour buds was assessed for its correlation with
clinicopathological features and molecular characteristics of each
case. Analysis of mismatch-protein expression was performed
using a four-marker panel (MLH1, MSH2, MSH6 and PMS2) as
previously described (Koelzer et al, 2012). For markers of EMT,
staining for NF-kBp65 and E-Cadherin was performed using a
matched multi-punch TMA from the same cohort containing two
spots each from the tumour centre and tumour front. NF-kBp65
immunostaining (Merck Millipore; Cat. no. D14E12; 1 : 1000) was
performed using a Bond Max Autostainer from Leica Micro-
systems (Wetzlar, Germany) with antigen retrieval in citrate buffer
at 100 1C for 30min; staining for E-cadherin (Dako, Baar,
Switzerland; Cat. no. NCH-38; 1 : 100) was performed as previously
described (Karamitopoulou et al, 2010). KRAS mutational status
(codon 12/13) and B-Raf mutational status was established using
pyrosequencing.
Statistical analysis. Differences in RKIP expression by tissue type
were evaluated using the Kruskal–Wallis test. Cutoff for RKIP
expression was derived using ROC curve analysis and the end
point survival (Zlobec et al, 2007), based on the current cohort.
The association of RKIP loss with clinicopathological features was
assessed using the w2, or Fisher’s exact test where appropriate.
Differences in survival time were displayed using Kaplan–Meier
curves and tested using the log-rank test in univariate analysis. The
independent prognostic effect of RKIP after adjusting for other
potential confounding factors was analysed using a Cox regression
model, after verification of the proportional hazards assumption.
Adjustment for multiple hypothesis testing was not undertaken
(Perneger, 1998), rather P-values o0.05 were considered statisti-
cally significant. Analyses were carried out using SAS (V9.2, SAS
Institute, Cary, NC, USA). This study complied with the REporting
recommendations for tumour MARKer prognostic studies
(REMARK) criteria (McShane et al, 2005).
RESULTS
Geographic analysis of RKIP protein expression. The highest
average expression of RKIP was consistently observed in normal
mucosa (27% RKIPþ cells), with a significant reduction in cancer
tissue (11% RKIPþ cells across all areas). Interestingly, within
CRCs, RKIP expression demonstrated considerable heterogeneity:
RKIP was lost progressively from the tumour centre towards the
invasive front and tumour buds (13.8%, 8.3% and 0.9% RKIP-
positivity, respectively; Po0.0001) (Figure 2D). Tumour buds
consistently showed the lowest frequency of RKIP expression, in
Table 1. Patient characteristics (n¼ 187)
Feature Frequency (n, %)
Gender (n¼186)
Male 92 (49.5)
Female 94 (50.5)
Age (years)
Mean (min, max) 68.1 (35–93)
Tumor size (mm)
Mean (min, max) 4.5 (1–12)
Histological subtype (n¼187)
Non-mucinous 163 (87.2)
Mucinous 24 (12.8)
Tumor location (n¼186)
Left-side 115 (61.8)
Right-side 45 (24.2)
Rectum 26 (14.0)
Tumor grade (n¼187)
G1–2 118 (63.1)
G3 69 (36.9)
pT (n¼187)
pT1–2 49 (26.2)
pT3–4 138 (73.8)
pN (n¼187)
pN0 95 (50.8)
pN1–2 92 (49.2)
pM (n¼186)
pM0 169 (90.9)
pM1 17 (9.1)
V (n¼187)
Vþ 29 (15.5)
V 158 (84.5)
L (n¼187)
Lþ 75 (40.1)
L 112 (59.9)
Tumor budding (n¼187)
Low-grade 105 (56.2)
High-grade 82 (43.9)
Tumor growth pattern (n¼187)
Infiltrating 134 (71.7)
Pushing 53 (28.3)
Post-operative therapy (n¼187)
None 69 (36.9)
Chemo 75 (40.1)
Chemoþ radio 42 (22.5)
Radio 1 (0.5)
Mismatch repair status (n¼186)
Proficient 173 (93.0)
Deficient 13 (7.0)
Table 1. ( Continued )
Feature Frequency (n, %)
KRAS mutation (codon 12/13), (n¼171)
Wild type 113 (66.1)
Mutated 58 (33.9)
Survival time (n¼186)
Months 47 (35–58)
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comparison to tumour centre and front, with 60.8% of cases
showing complete loss of RKIP expression in this area.
Association of RKIP expression with clinicopathological
features. RKIP loss in the tumour centre independently predicted
more frequent distant metastatic disease (P¼ 0.0307). Of 17
patients with distant metastasis, 12 showed loss of RKIP expression
in the primary tumour (Table 2). Further, a strong trend towards
vascular invasion (P¼ 0.0506) was observed. In patients with loss
of RKIP expression, vascular invasion was observed in 21.2% of
cases, while only 10.8% of patients with maintained RKIP
expression in their primary tumours presented with this feature.
Further, RKIP-negative tumours showed an aggressive phenotype
with invasive tumour border configuration in up to 81.2% of cases,
independent of the geographic distribution of RKIP loss (infil-
trative tumour growth, centre: P¼ 0.0084; front P¼ 0.038;
(Tables 2 and 3). At the same time, intense tumour budding
(410 tumour buds per HPF) was observed in tumours with RKIP
loss in tumour centre or front (centre: P¼ 0.0112; front
P¼ 0.0017). RKIP loss at the invasive front correlated inversely
with tumour size (P¼ 0.0229), and identified a trend towards
vascular and lymphatic invasion (P¼ 0.0587 and P¼ 0.0514
respectively), while no association with nodal or distant metastatic
disease was observed (Table 3). Loss of RKIP was frequent in
tumour buds, with 60.8% of cases demonstrating complete loss in
this geographic area of CRC. Within tumour buds themselves, no
association of RKIP expression with clinicopathological features
was observed (Supplementary Table S3).
Association of RKIP expression with survival. Loss of RKIP
expression in the tumour centre predicted a significantly increased
hazard ratio for death (HR (95%CI): 2.13 (1.27–3.56); P¼ 0.0042),
independently of TNM classification and therapy (P¼ 0.0474)
(Figure 3A, Tables 2 and 4). In contrast, RKIP expression at the
front and in tumour buds did not show utility for the prediction of
survival (HR (95% CI): 1.37 (0.84–2.22); P¼ 0.2082 and HR (95%
CI): 0.98 (0.58–1.68); P¼ 0.9467, respectively) (Figure 3B and C).
We further analysed the predictive value of RKIP expression for
survival in the tumour centre stratified by stage: In stage III CRC, a
significant correlation between maintained RKIP expression and
prolonged survival was observed (P¼ 0.01), while early-stage
patients did not derive prognostic benefit (P¼ 0.9585) (Figure 4A
and B). Further subgroup analysis demonstrated that the
prognostic value of RKIP expression in the tumour centre was
Table 2. Expression of RKIP in the tumor centre and association with
clinicopathological features (n¼187)
RKIP (n, %)
Feature
Negative
(o10%)
Positive
(X10%) P-value
Gender (n¼186)
Male 43 (50.6) 49 (48.5) 0.7781
Female 42 (49.4) 52 (41.5) —
Age (years)
Mean (min, max) 67.4 (35, 89) 68.7 (36, 93) 0.4496
Tumor size (mm)
Mean (min, max) 4.7 (1, 12) 4.3 (1.2, 9.0) 0.2931
Histological subtype (n¼187)
Non-mucinous 73 (85.9) 90 (88.2) 0.6319
Mucinous 12 (14.1) 12 (11.8) —
Tumor location (n¼186)
Left-side 53 (63.1) 62 (60.8) 0.9016
Right-side 12 (14.3) 14 (13.7) —
Rectum 19 (22.6) 26 (25.5) —
Tumor grade (n¼187)
G1–2 48 (56.5) 70 (68.6) 0.0863
G3 37 (43.5) 32 (31.4) —
pT (n¼187)
pT1–2 23 (27.1) 26 (25.5) 0.8081
pT3–4 62 (72.9) 76 (74.5) —
pN (n¼187)
pN0 41 (48.2) 54 (52.9) 0.5216
pN1–2 44 (51.8) 48 (47.1) —
pM (n¼186)
pM0 73 (85.9) 96 (95.1) 0.0307
pM1 12 (14.1) 5 (5.0) —
V (n¼187)
Vþ 18 (21.2) 11 (10.8) 0.0506
V 67 (78.8) 91 (89.2) —
L (n¼187)
Lþ 39 (45.9) 36 (35.3) 0.1413
L 46 (54.1) 66 (64.7) —
Tumor budding (n¼148)
Low-grade 47 (72.3) 43 (51.8) 0.0112
High-grade 18 (27.7) 40 (48.2) —
Tumor growth pattern (n¼187)
Infiltrating 69 (81.2) 65 (63.7) 0.0084
Pushing 16 (18.8) 37 (36.3) —
Mismatch repair status (n¼186)
Proficient 75 (88.2) 98 (97.0) 0.0191
Deficient 10 (11.8) 3 (3.0) —
Table 2. ( Continued )
RKIP (n, %)
Feature
Negative
(o10%)
Positive
(X10%) P-value
B-RAF mutation (V600E) (n¼180)
Wild type 70 (87.5) 93 (93.0) 0.2099
Mutated 10 (12.5) 7 (7.0) —
KRAS mutation (codon 12/13), (n¼171)
Wild type 51 (67.1) 62 (65.3) 0.8004
Mutated 25 (32.9) 33 (34.7) —
Hazard ratio for death with loss of RKIP (n¼186)
HR (95%CI) 2.13 (1.27–3.56) 0.0042
Adjuvant therapy (n¼187)
None 30 (43.5) 55 (46.6) 0.6781
Treated 39 (56.5) 63 (53.4) —
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maintained in stage III CRC patients receiving chemotherapy
(P¼ 0.002), (Figure 4C).
Correlative analysis of RKIP Expression with E-Cadherin and
NF-jB. Correlative analysis of average RKIP expression in the
tumour centre with markers of EMT demonstrated a significant
positive correlation with staining for E-Cadherin in this geographic
area of CRC (Po0.0001; r¼ 0.4). Cases with loss of RKIP
infrequently demonstrated maintained E-Cadherin expression,
indicating loss of cell adhesion. Further, RKIP expression in
the tumour centre correlated inversely with an increased frequency
of nuclear translocation of NF-kB (P¼ 0.0002; r¼  0.156),
indicating that loss of RKIP correlates with more nuclear positivity
for the marker and increased activation of the NF-kB signalling
pathway.
Analysis of RKIP expression in a molecular pathology context.
As RKIP serves a central role in the regulation of the mitogen-
activated kinase (MAPK) signalling cascade, which is initialised by
Raf-1, RKIP protein expression was analysed in the context of
KRAS and activating B-Raf (V600) mutation frequency. Interest-
ingly, both KRAS and activating B-Raf mutations did not show
an impact on RKIP protein expression in any of the areas
analysed (Tables 2 and 3 and Supplementary Table S3). RKIP
maintained its prognostic significance when adjusting for B-Raf
status (P¼ 0.0051; HR (95% CI): 2.15 (1.26–3.67)) as well as
KRAS-mutation (P¼ 0.0029; HR (95% CI): 2.28 (1.3–3.9)) in
multivariate analysis. B-Raf and KRAS mutations were not
prognostic in our series (P¼ 0.958 and P¼ 0.1986 respectively).
Loss of RKIP expression in the tumour centre and in tumour
buds was significantly more common in MMR-deficient cancers
(P¼ 0.0191 and P¼ 0.05, respectively), while no association was
observed at the tumour front.
DISCUSSION
This study presents a novel geographic analysis of RKIP expression
pattern in primary CRC in accordance with the REMARK
guidelines for biomarker prognostic studies (McShane et al,
2005). By these means, we identify considerable intratumoural
heterogeneity of RKIP expression in primary CRC. Interestingly,
the prognostic value of RKIP expression in CRC is shown to be
limited to the tumour centre. In this geographic area, loss of RKIP
Table 3. Expression of RKIP in the tumor front and association with
clinicopathological features (n¼187)
RKIP (n, %)
Feature
Negative
(o10%)
Positive
(X10%) P-value
Gender (n¼186)
Male 43 (50.0) 49 (49.0) 0.8918
Female 43 (50.0) 51 (51.0) —
Age (years)
Mean (min, max) 67.6 (35, 89) 68.6 (36, 93) 0.5366
Tumor size (mm)
Mean (min, max) 4.9 (1, 12) 4.2 (1.2, 3.0) 0.0229
Histological subtype (n¼187)
Non-mucinous 73 (84.9) 90 (89.1) 0.3893
Mucinous 13 (15.1) 11 (10.9) —
Tumor location (n¼186)
Left-side 54 (63.5) 61 (60.4) 0.6518
Right-side 13 (15.3) 13 (12.9) —
Rectum 18 (21.2) 27 (26.7) —
Tumor grade (n¼187)
G1–2 48 (55.8) 70 (69.3) 0.0567
G3 38 (44.2) 31 (30.7) —
pT (n¼187)
pT1–2 21 (24.4) 28 (27.7) 0.6086
pT3–4 65 (75.6) 73 (72.3) —
pN (n¼187)
pN0 39 (45.4) 56 (55.5) 0.1687
pN1–2 47 (54.7) 45 (44.6) —
pM (n¼186)
pM0 75 (87.2) 94 (94.0) 0.1091
pM1 11 (12.8) 6 (6.0) —
V (n¼187)
Vþ 18 (20.9) 11 (10.9) 0.0587
V 68 (79.1) 90 (89.1) —
L (n¼187)
Lþ 41 (47.7) 34 (33.7) 0.0514
L 45 (52.3) 67 (66.3) —
Tumor budding (n¼148)
Low-grade 50 (74.6) 40 (49.4) 0.0017
High-grade 17 (25.4) 41 (50.6) —
Tumor growth pattern (n¼187)
Infiltrating 68 (79.1) 66 (65.4) 0.038
Pushing 18 (20.9) 35 (34.7) —
Mismatch repair status (n¼186)
Proficient 77 (89.5) 96 (96.0) 0.0847
Deficient 9 (10.5) 4 (4.0) —
Table 3. ( Continued )
RKIP (n, %)
Feature
Negative
(o10%)
Positive
(X10%) P-value
B-RAF mutation (V600E) (n¼180)
Wild type 71 (86.6) 92 (93.9) 0.0957
Mutated 11 (13.4) 6 (6.1) —
KRAS mutation (codon 12/13), (n¼171)
Wild type 54 (71.1) 59 (62.1) 0.2194
Mutated 22 (29.0) 36 (37.9) —
Hazard ratio for death with loss of RKIP (n¼186)
HR (95%CI) 1.37 (0.84–2.22) 0.2082
Adjuvant therapy (n¼187)
None 30 (43.5) 56 (47.5) 0.5983
Treated 39 (56.5) 62 (52.5) —
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is a valuable marker for the prediction of aggressive histopatho-
logical features, metastatic relapse and poor outcome in CRC
patients and correlates with histomorphological features of EMT,
loss of E-Cadherin and NF-kB activation.
The present study contributes to the understanding of the role
of RKIP in CRC in several ways. In a first step, we analyse RKIP
expression in a well-characterised set of CRC-patients using a
novel geographic approach towards protein expression analysis by
immunohistochemistry. Our results illustrate a considerable
biological variation of RKIP protein expression in primary CRC
with progressive loss of RKIP from the tumour centre towards the
tumour front and almost complete absence in tumour buds.
Previously conducted studies have been based on tissue microarray
analysis (Al-Mulla et al, 2006; Minoo et al, 2007; Zlobec et al, 2008;
Doyle et al, 2013), which may cause considerable underestimation
of the true distribution of RKIP expression based on the well-
described genetic heterogeneity of CRC (Gerlinger et al, 2012). A
first indication of intratumoural heterogeneity of RKIP expression
in CRC was provided by systematic analysis of proteins from
different signalling pathways in the tumour centre and invasive
front in a previously conducted study by our group
(Karamitopoulou et al, 2011). However, a systematic protein
expression analysis in all histological areas of CRC, the examina-
tion of RKIP expression in tumour buds and the systematic
investigation of the molecular pathology context of RKIP
expression was not performed.
Second, we show that loss of RKIP expression in the tumour
centre is strongly associated with aggressive histopathological
features, metastatic relapse and poor clinical outcome independent
of TNM stage and postoperative therapy. This data confirms
previous studies that identify RKIP as a predictive marker of
metastasis and decreased survival outcome in CRC (Al-Mulla et al,
2006; Minoo et al, 2007; Zlobec et al, 2008; Doyle et al, 2013). In
these studies, both single-punch (Al-Mulla et al, 2006; Minoo et al,
2007; Zlobec et al, 2008) and multi-punch TMAs (Doyle et al,
2013) from the tumour centre were used in non-geographic
analysis. Interestingly, the prognostic value of RKIP in geographic
analysis is restricted to the tumour centre, confirming these
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Figure 2. (A) RKIP-stained full-tissue section with exemplary identification of the geographic areas tumour centre, tumour front and tumour
buds and high-power fields selected for evaluation (B) Immunohistochemistry for RKIP showing normal mucosa, tumour centre, tumour front
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Figure 3. Prognostic effects of RKIP expression in tumour centre, tumour front and tumour buds. (A) Loss of RKIP expression in the tumour centre
predicted a significantly increased hazard ratio for death (HR (95% CI): 2.13 (1.27–3.56); P¼ 0.0042). (B, C) In contrast, no impact of RKIP expression
on outcome was observed at the tumour front and in tumour buds (HR (95% CI): 1.37 (0.84–2.22); P¼0.2082 and HR (95% CI): 0.98 (0.58–1.68);
P¼0.9467, respectively).
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previous studies that were limited to tumor samples of this area. In
correlative subgroup analysis, stage III patients of our series with
maintained RKIP expression in the tumor centre derived
significant prognostic benefit, while the prognosis of stage II
patients was not influenced by RKIP expression. These results
based on geographic analysis of RKIP protein expression contrast
with previously published studies that identify a significant
prognostic impact of RKIP expression in early-stage CRC patients
(Al-Mulla et al, 2006; Zlobec et al, 2008; Doyle et al, 2013).
Differences in study design, analytical methods (antibodies,
staining protocols), the material used (TMA vs full tissue sections),
therapy and patient selection may contribute to the observed
discrepancies in the survival analysis of the early-stage subset.
Clearly, the prognostic value of RKIP expression of the stage II
subset needs to be further studied, ideally in randomized
prospective clinical trials.
Third, we demonstrate a maintained correlation between RKIP
expression in the tumour centre and improved survival outcome in
stage III patients receiving chemotherapy. A direct comparison
between treated and untreated stage III patients was not possible
with adequate statistical power in our study cohort. This is due to
the low frequency of stage III patients who did not receive
chemotherapeutic agents in our series, as adjuvant treatment
corresponds to the standard of care for CRC patients presenting
with nodal metastasis. Consequently, studies analysing impact of
RKIP on therapy response in CRC are few: Minoo et al (2007) first
demonstrated an increased response rate in a retrospective analysis
of CRC patients receiving adjuvant therapy. An enhanced response
to chemotherapeutic agents dependent on RKIP expression has
also previously been demonstrated in several other epithelial
malignancies, including breast and prostate cancer (Chatterjee
et al, 2004). On a mechanistic level, RKIP has been shown to
regulate tumour-cell resistance to apoptotic stimuli through the
induction of TRAIL (Baritaki et al, 2007). Al-Mulla et al (2012)
have provided further insights into how RKIP expression
effectively sensitises CRC cell lines to chemotherapeutic and
immunotherapeutic drugs: RKIP enhances the stability of Kelch-
like ECH-associated protein 1 (KEAP 1) inhibiting the activation
of NF-E2-related nuclear factor 2 (NRF2)-responsive genes,
including intracellular antioxidants and redox-regulating genes.
Based on these mechanistic insights and the available retrospective
clinical data, RKIP expression in the tumour centre of CRC may be
a promising future predictive marker for evaluation in randomized
multicenter trials and prospective studies.
Fourth, the current study demonstrates a strong correlation of
the loss of RKIP with morphological hallmarks of EMT such as an
invasive border configuration and strong tumour budding activity
both in the tumour centre and tumour front. On a signalling level,
we identify strong correlations of RKIP-loss in the tumour centre
with nuclear translocation of NF-kB and loss of E-cadherin
expression. This confirms previous data by our group that
identified loss of RKIP as a potential feature of a protein
phenotype for the prediction of tumour budding in CRC
(Karamitopoulou et al, 2010). We now further advance this
analysis by correlation of geographic expression patterns of RKIP
with features of EMT both on a morphological and signalling level
and RKIP expression profiling of tumour buds using full-tissue
sections. These data provide further evidence of the association of
RKIP loss with features of EMT as histological hallmarks of
biological – and clinical – aggressiveness in CRC. RKIP has been
suggested to have a major and pleiotropic role for negative
regulation of EMT through inhibition of both Raf-1/MEK/ERK
and NF-kB mediated signalling (Wu and Bonavida, 2009). RKIP
also negatively influences the expression of b-catenin, SNAIL and
SLUG by enhancing glycogen synthase kinase-3b signalling, and
downregulates central mediators of cell cycle progression and cell
motility (Al-Mulla et al 2011a, b). Loss of RKIP disinhibits NF-kB,
which contributes to the induction of metastasis through the
activation of its downstream transcriptional target SNAIL in cancer
cells (Wu et al, 2009); SNAIL contributes to the induction of EMT
through positive-feedback regulation of WNT-signalling resulting
in downregulation of E-Cadherin and nuclear translocation of
b-catenin (Wu and Bonavida, 2009). The current study provides
further evidence of a link between loss of RKIP and activation of
EMT on a histopathologic level based on the presence of tumour
budding and an invasive tumour border configuration in cases
with loss of RKIP at the tumour centre or front. Further, we
Table 4. Multivariate Cox regression analysis of RKIP expression in the
tumor center and other established prognostic variables
HR (95% CI) P-value
RKIP expression
Negative (o10%) 1.78 (1.01–3.07) 0.0474
Positive (410%) 1.0 —
T-Stage
pT1–2 1.0 0.5021
pT3–4 1.34 (0.57–3.17) —
N-Stage
pN0 1.0 0.0001
pN1–2 4.15 (2.0–8.6) —
M-Stage
pM0 1.0 0.0002
pM1 3.44 (1.79–6.6)
Postop therapy
No 1.0 0.1127
Yes 0.61 (0.33–1.12) —
P=0.002; center
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Figure 4. Prognostic effects of RKIP expression in tumour centre stratified by stage and therapy. (A) No impact on prognosis was observed in
early-stage patients (P¼ 0.9585). (B) Stage III patients with maintained RKIP expression derived a significant survival benefit (P¼0.01). (C) The
prognostic value of RKIP in the tumor centre was maintained in stage III CRC patients receiving adjuvant chemotherapy (P¼0.002).
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demonstrate frequent RKIP loss in tumour buds themselves,
implicating that loss of RKIP may be an early event during EMT.
In correlative analysis, we identify a significant correlation between
loss of RKIP, E-Cadherin negativity and nuclear translocation of
NF-kB, in agreement with the abovementioned mechanistic
studies.
Next, we performed a novel correlative analysis of RKIP protein
expression in the context of activating B-Raf (V600) and KRAS
mutations in each histological zone. Interestingly, no impact of
B-Raf and KRAS mutational status on RKIP protein expression or
survival was observed. While the inhibitory function of RKIP on
Raf-1 signalling is well described, previous studies have provided
conflicting results on the ability of RKIP to inhibit wild-type B-Raf
kinase (Park et al, 2005; Trakul et al, 2005). For KRAS, no direct
regulatory effect of RKIP has been identified, yet RKIP interferes
with the association of the central RAS-target Raf-1 with MEK
(Yeung et al, 1999). It has not been investigated whether the
oncogenic effects of a constitutive activation of the B-Raf or KRAS-
pathway may be limited by maintained RKIP expression. Here, we
demonstrate first evidence that both B-Raf and KRAS mutation do
not correlate with a change of RKIP protein expression in CRC in a
well-characterised cohort.
In the context of MMR deficiency, an increased frequency of
RKIP-loss was observed in the tumour centre and in tumour buds,
yet no association was observed at the tumour front. Previous
studies have provided conclusive evidence of a strong prognostic
effect of RKIP expression in MMR-deficient CRC, an effect that
was attributed to anti-apoptotic effects in the context of
microsatellite deficiency (Minoo et al, 2007). However, a positive
correlation between loss of RKIP expression and MMR proteins
was not observed (Al-Mulla et al, 2006; Minoo et al, 2007).
Silencing of the RKIP promoter through methylation of CpG
islands has been identified as a possible mechanism leading to
RKIP loss in MMR-proficient CRC (Al-Mulla et al, 2008). Further,
we have previously characterised a significant relation between
decreased RKIP expression and high CpG island methylator
phenotype in CRC (Zlobec et al, 2011). As MMR-deficient cancers
demonstrate the highest degree of promoter methylation
(Bettington et al, 2013), the observed increased frequency of
RKIP-loss may be indirect evidence of RKIP promoter-silencing
through aberrant methylation. Interestingly, conflicting results
were provided by a previous study of RKIP promoter methylation
in CRC: In 28 selected cases with loss of RKIP, no methylation of
the promoter region of RKIP could be identified by methylation-
specific PCR independent of MMR status (Minoo et al, 2007).
However, these results may be influenced by the small number of
patients investigated, the resolution of the method employed as
well as the selected promoter region, and should be further
analysed.
This study must be interpreted in the context of its limitations.
First, a differentiation between phosphorylated RKIP and unmo-
dified RKIP protein could not be detected based on the
immunohistochemical expression analysis performed. Experimen-
tal studies have provided conclusive evidence that RKIP can be
phosporylated at serine 153 (Ser-153) by protein kinase C, which
leads to dissociation from Raf-1 (Corbit et al, 2003). The analysis of
the contribution of pRKIP to the prognostic impact of RKIP
expression may be an interesting leverage point for further study.
Further, mismatch repair status was determined using a four-
marker panel for MMR-protein expression, which does not allow a
specific differentiation between sporadic and hereditary (HNPCC-
associated) microsatellite instable CRCs (Cicek et al, 2011). Owing
to the low frequency of MMR-deficient cancers and limited patient
material, a specific differentiation between HNPCC and sporadic
microsatellite instable CRC patients was not attempted.
The present study provides a detailed characterisation of
RKIP expression patterns in CRC in correlation with tumour
morphology, molecular features and prognosis. By geographic
protein expression analysis, we demonstrate that loss of RKIP
expression in the tumour centre is strongly associated with both
the biological and clinical behaviour of the cancer. First, loss of
RKIP expression in the tumour centre correlates with the features
of EMT and is most predictive of aggressive histopathological
features including tumour budding, an infiltrative tumour border
configuration, vascular invasion and distant metastasis. Second,
RKIP expression in the tumour centre holds independent
prognostic value that is maintained under chemotherapeutic
treatment of advanced CRC. Third, molecular analysis demon-
strated that RKIP expression is not influenced by B-Raf or KRAS
mutations. We therefore recommend the evaluation of RKIP
expression in the tumour centre of CRC as a biomarker for
prospective validation in randomized multicenter trials.
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